Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 193,300 shares, an increase of 48.2% from the February 13th total of 130,400 shares. Approximately 36.2% of the company’s shares are short sold. Based on an average daily volume of 218,900 shares, the days-to-cover ratio is presently 0.9 days.

Bone Biologics Price Performance

Shares of Bone Biologics stock opened at $0.83 on Monday. Bone Biologics has a 12-month low of $0.71 and a 12-month high of $4.25. The company’s fifty day simple moving average is $0.99 and its two-hundred day simple moving average is $1.27.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.